Ovarian Cancer Risk and Prohibitin Polymorphism in Polish Women
Author Information
Author(s): Jakubowska Anna, Gronwald Jacek, Menkiszak Janusz, Górski Bohdan, Huzarski Tomasz, Byrski Tomasz, Benner Axel, Lubiński Jan, Scott Rodney J, Hamann Ute
Primary Institution: Pomeranian Medical University
Hypothesis
Does the PHB 3'UTR polymorphism modify ovarian cancer risk in BRCA1 mutation carriers?
Conclusion
The PHB 3'UTR polymorphism does not modify ovarian cancer risk in women carrying Polish BRCA1 founder mutations.
Supporting Evidence
- No association was found between the PHB 3'UTR genotypes and ovarian cancer risk.
- The study included 127 ovarian cancer cases and 127 matched controls.
- The odds ratio for the CT+TT genotypes was 1.34 with a 95% confidence interval of 0.59–3.11.
Takeaway
This study looked at whether a specific gene change affects the risk of ovarian cancer in women with a certain genetic mutation, and found it does not.
Methodology
A case-control study with 127 ovarian cancer cases and 127 matched controls, genotyping was performed using PCR-based restriction fragment length polymorphism analysis.
Potential Biases
Potential bias due to the presence of relatives among study subjects was addressed by performing analyses excluding related individuals.
Limitations
The study may not have detected an association due to its smaller sample size for ovarian cancer compared to breast cancer.
Participant Demographics
Participants were Polish women carrying one of three common BRCA1 founder mutations.
Statistical Information
P-Value
0.88
Confidence Interval
95% CI, 0.59–3.11
Statistical Significance
p = 0.88
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website